Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
15.97
+1.30 (8.86%)
At close: Oct 2, 2025, 4:00 PM EDT
15.92
-0.05 (-0.31%)
Pre-market: Oct 3, 2025, 5:24 AM EDT

Ginkgo Bioworks Holdings Statistics

Total Valuation

DNA has a market cap or net worth of $885.14 million. The enterprise value is $840.28 million.

Market Cap885.14M
Enterprise Value 840.28M

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025, after market close.

Earnings Date Nov 11, 2025
Ex-Dividend Date n/a

Share Statistics

DNA has 55.43 million shares outstanding. The number of shares has increased by 7.76% in one year.

Current Share Class 43.82M
Shares Outstanding 55.43M
Shares Change (YoY) +7.76%
Shares Change (QoQ) +1.14%
Owned by Insiders (%) 17.40%
Owned by Institutions (%) 61.76%
Float 38.68M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.72
Forward PS 5.01
PB Ratio 1.44
P/TBV Ratio 1.62
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.64
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.41, with a Debt / Equity ratio of 0.70.

Current Ratio 5.41
Quick Ratio 5.14
Debt / Equity 0.70
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -3,135.87

Financial Efficiency

Return on equity (ROE) is -43.59% and return on invested capital (ROIC) is -15.83%.

Return on Equity (ROE) -43.59%
Return on Assets (ROA) -12.90%
Return on Invested Capital (ROIC) -15.83%
Return on Capital Employed (ROCE) -25.99%
Revenue Per Employee $276,757
Profits Per Employee -$377,930
Employee Count834
Asset Turnover 0.16
Inventory Turnover n/a

Taxes

Income Tax -895,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +110.13% in the last 52 weeks. The beta is 1.55, so DNA's price volatility has been higher than the market average.

Beta (5Y) 1.55
52-Week Price Change +110.13%
50-Day Moving Average 12.36
200-Day Moving Average 10.01
Relative Strength Index (RSI) 72.78
Average Volume (20 Days) 1,639,643

Short Selling Information

The latest short interest is 6.27 million, so 11.32% of the outstanding shares have been sold short.

Short Interest 6.27M
Short Previous Month 7.10M
Short % of Shares Out 11.32%
Short % of Float 16.22%
Short Ratio (days to cover) 3.86

Income Statement

In the last 12 months, DNA had revenue of $230.82 million and -$315.19 million in losses. Loss per share was -$5.86.

Revenue230.82M
Gross Profit 182.32M
Operating Income -294.77M
Pretax Income -316.09M
Net Income -315.19M
EBITDA -230.79M
EBIT -294.77M
Loss Per Share -$5.86
Full Income Statement

Balance Sheet

The company has $473.69 million in cash and $428.83 million in debt, giving a net cash position of $44.86 million or $0.81 per share.

Cash & Cash Equivalents 473.69M
Total Debt 428.83M
Net Cash 44.86M
Net Cash Per Share $0.81
Equity (Book Value) 612.95M
Book Value Per Share 11.06
Working Capital 426.31M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$237.71 million and capital expenditures -$36.46 million, giving a free cash flow of -$274.17 million.

Operating Cash Flow -237.71M
Capital Expenditures -36.46M
Free Cash Flow -274.17M
FCF Per Share -$4.95
Full Cash Flow Statement

Margins

Gross margin is 78.99%, with operating and profit margins of -127.71% and -136.56%.

Gross Margin 78.99%
Operating Margin -127.71%
Pretax Margin -136.94%
Profit Margin -136.56%
EBITDA Margin -99.99%
EBIT Margin -127.71%
FCF Margin n/a

Dividends & Yields

DNA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -7.76%
Shareholder Yield -7.76%
Earnings Yield -35.61%
FCF Yield -30.97%
Dividend Details

Analyst Forecast

The average price target for DNA is $9.00, which is -43.64% lower than the current price. The consensus rating is "Strong Sell".

Price Target $9.00
Price Target Difference -43.64%
Analyst Consensus Strong Sell
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.

Last Split Date Aug 20, 2024
Split Type Reverse
Split Ratio 1:40

Scores

DNA has an Altman Z-Score of -6.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -6.51
Piotroski F-Score 3